Topoisomerase I inhibitors: topotecan and irenotecan.
Creemers
G J
GJ
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Lund
B
B
Verweij
J
J
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy; D059004:Topoisomerase I Inhibitors; D019772:Topotecan
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin